https://orcid.org/0000-0002-3437-9392
References
- UNAIDS. Ending AIDS progress towards the 90- 90-90 targets. Geneva: Global AIDS update; 2017.
- World Health Organization. Latest HIV estimates and updates on HIV policies uptake. Geneva; 2020.
- Girum T, Wasie A, Worku A. Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: a time series analysis. BMC Infect Dis. 2018;18:320. doi:10.1186/s12879-018-3214-6
- The Ethiopian Public Health Institute. HIV related estimats and projections in Ethiopia for the year-2019. Adis Ababa: EPHI; 2020.
- The Ethiopian Public Health Institute. HIV related estimates and projections for Ethiopia. Adis Ababa; 2017.
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trails Group 320 Study Team. N Engl J Med. 1997;337:725–733. doi:10.1056/NEJM199709113371101
- Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:e31591.
- Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4(6):459–466. doi:10.1097/COH.0b013e328331dea5
- World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. Geneva, Switzerland: WHO; 2016.
- World Healths Organization. WHO guidelines on the use of CD4, viral load and early infant diagnosis (EID) tests for initiation and monitoring of ART. Geneva: WHO; 2015.
- Gezie LD, Gelaye KA, Worku AG, et al. Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia. BMC Res Notes. 2017;10:1–7.
- Lenjiso GA, Endale BS, Bacha YD. Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia. BMC Public Health. 2019;19(1):1–10. doi:10.1186/s12889-019-7078-5
- Nigusie T, Asfaw D, Belete B. Determinants of change in CD4 count and relationship with survival among children with HIV in Ethiopia. AIDS Care. 2020;33:1237–1241.
- Rossetti B, Baldin G, Sterrantino G, et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naive patients: results from a multicenter cohort study. Antiviral Res. 2019;169:104552. doi:10.1016/j.antiviral.2019.104552
- Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of Dolutegravir based Regimen in a resource-limited setting: an observational retrospective study in Ethiopia. HIV/AIDS. 2021;13:709.
- Ndashimye E, Arts EJ. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: impact in low-and middle-income settings. Int J Infect Dis. 2021;105:298–303. doi:10.1016/j.ijid.2021.03.018
- Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS One. 2016;11(10):e0162775. doi:10.1371/journal.pone.0162775
- Limmade Y, Fransisca L, Rodriguez-Fernandez R, et al. HIV treatment outcomes following antiretroviral therapy initiation and monitoring: a workplace program in Papua, Indonesia. PLoS One. 2019;14(2):e0212432. doi:10.1371/journal.pone.0212432